Every Form 4 that Puma Biotechnology Inc (PBYI) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PBYI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PBYI filings page.
Puma Biotechnology President and CEO Alan H. Auerbach reported an open-market sale of 44,058 shares of common stock at $8.263 per share on July 6, 2026. After this transaction, he still directly holds 7,261,671 shares, suggesting it represents a small portion of his stake. The sale was executed under a pre-established Rule 10b5-1(c) sell-to-cover program adopted on December 17, 2020, indicating it was part of a pre-planned trading arrangement.
PUMA Biotechnology officer Douglas M. Hunt reported an open-market sale of company stock. On the reported date, he sold 8,460 shares of PUMA Biotechnology common stock at an average price of $8.263 per share. After this transaction, he directly holds 196,841 shares of common stock. The filing notes that the sale occurred under a Rule 10b5-1(c) sell-to-cover program adopted on December 14, 2020, indicating the trade was executed pursuant to a pre-arranged trading plan.
PUMA Biotechnology Chief Financial Officer Maximo F. Nougues sold 9,386 shares of common stock on July 6, 2026 in an open-market transaction at an average price of $8.263 per share. After this sale, he directly holds 230,637 shares of the company’s common stock.
The transaction was executed under a pre-arranged Rule 10b5-1(c) sell-to-cover program, originally adopted on December 14, 2020, indicating it followed a preset trading plan rather than discretionary market timing.
Puma Biotechnology director Troy Edward Wilson reported both a stock grant and a sale of shares of common stock. He received 27,000 Restricted Stock Units (RSUs) that vest in full on the earlier of one year from grant or the next annual shareholder meeting, subject to his continued service with the company.
Wilson also completed an open-market sale of 10,800 shares at a weighted average price of $7.1989 per share under a pre-arranged Rule 10b5-1(c) trading plan adopted on 03-12-2025. Following these transactions, he holds 59,750 shares directly, plus 550 shares indirectly through accounts for two children.
Puma Biotechnology director Brian M. Stuglik reported both an equity grant and a share sale. On June 11, 2026, he acquired 27,000 shares of common stock at $0.00 per share as a grant of Restricted Stock Units that vest in full on the earlier of the one-year anniversary of the grant date or the next annual shareholder meeting, subject to continued service. On June 12, 2026, he executed an open-market sale of 8,100 common shares at a weighted average price of $7.1989 per share, in multiple trades between $6.98 and $7.32, under a Rule 10b5-1(c) trading plan adopted on March 12, 2025. Following these transactions, he directly holds 113,858 common shares.
PUMA Biotechnology director Adrian Senderowicz reported both an equity grant and a stock sale. On June 11, 2026, he received 27,000 shares of Common Stock as Restricted Stock Units that vest in full on the earlier of the one-year anniversary of the grant date or the next annual shareholder meeting, subject to continued service.
On June 12, 2026, he sold 27,000 shares of Common Stock in an open-market transaction at a weighted average price of $7.1967 per share, with individual sale prices ranging from $6.98 to $7.32. The sale was effected pursuant to a Rule 10b5-1(c) trading plan adopted on March 12, 2025, and he held 27,000 shares directly after the transactions.
MILLER MICHAEL PATRICK reported acquisition or exercise transactions in this Form 4 filing.
Puma Biotechnology director Michael Patrick Miller received an equity award in the form of restricted stock units. He was granted 27,000 shares of common stock at no cash cost to him, increasing his directly held stake to 81,000 shares after this grant.
The restricted stock units vest in full on the earlier of one year from the grant date or the next annual shareholder meeting, as long as he continues serving the company. This is a compensation-related grant rather than an open-market purchase or sale.
PUMA Biotechnology director Jay M. Moyes reported both an equity grant and a share sale. On June 11, 2026, he received 27,000 shares as a grant described as Restricted Stock Units that vest in full on the earlier of the one-year anniversary of grant or the next annual shareholder meeting, subject to continued service.
On June 12, 2026, he sold 22,000 shares of common stock in an open-market transaction pursuant to a Rule 10b5-1(c) trading plan adopted on March 12, 2025, at a weighted-average price of $7.218 per share across trades ranging from $6.98 to $7.32. Following these transactions, he directly holds 58,322 shares of common stock.
PUMA Biotechnology director Allison Dorval reported both an equity grant and a share sale. On June 11, 2026, she received 27,000 Restricted Stock Units that vest in full on the earlier of the one-year anniversary of grant or the next annual shareholder meeting, subject to continued service. On June 12, 2026, she made an open-market sale of 11,610 common shares at a weighted average price of $7.1989 per share under a Rule 10b5-1(c) trading plan adopted on 03-12-2025. After these transactions, Dorval directly holds 90,780 common shares.
Cesano Alessandra reported acquisition or exercise transactions in this Form 4 filing.
PUMA Biotechnology director Alessandra Cesano reported an equity award of 27,000 shares of Common Stock on June 11, 2026. The award is in the form of Restricted Stock Units that vest in full on the earlier of the one-year anniversary of the grant date or the next annual shareholder meeting, subject to her continued service with the company.
Following this grant, Cesano directly holds 68,850 shares. This is a compensation-related grant, not an open-market purchase.
PUMA BIOTECHNOLOGY, INC. President and CEO Alan H. Auerbach reported equity awards that increase his direct holdings. On February 18, 2026, he received a grant of stock options for 227,474 shares at an exercise price of $0.00 per share.
On the same date, he was also granted 159,778 shares of common stock in the form of restricted stock units. Both the RSUs and the options vest in four equal installments on July 1, 2026, January 1, 2027, July 1, 2027 and January 1, 2028, subject to continued employment and possible acceleration in certain events.
PUMA BIOTECHNOLOGY, INC. executive Douglas M. Hunt reported new equity awards consisting of stock options and restricted stock units. He was granted stock options for 70,321 shares at no exercise price shown here and 49,394 restricted stock units, both in direct ownership. These awards vest in four equal installments on July 1, 2026, January 1, 2027, July 1, 2027, and January 1, 2028, conditioned on his continued service with the company through each vesting date.
Puma Biotechnology, Inc. reported that its Chief Financial Officer, Maximo F. Nougues, received new equity awards on February 18, 2026. He was granted a stock option for 66,541 shares at an exercise price of $0.00 per share and 46,739 Restricted Stock Units (RSUs) representing shares of common stock.
According to the award terms, both the RSUs and the option vest in four equal installments: one-fourth on July 1, 2026, January 1, 2027, July 1, 2027, and January 1, 2028, in each case conditioned on his continued service with the company through the applicable vesting date.
Puma Biotechnology President and CEO Alan H. Auerbach, who is also a director and 10% owner of the company, reported two open-market sales of Puma common stock. On January 6, 2026, he sold 16,938 shares at a price of $5.844 per share. On January 7, 2026, he sold an additional 18,012 shares at $5.879 per share.
After these transactions, Auerbach beneficially owned 7,145,951 shares of Puma common stock directly. The filing notes that these transactions were made under a Rule 10b5-1(c) trading plan adopted on December 17, 2020, which is a pre-arranged plan intended to allow insiders to sell shares according to preset instructions.
Puma Biotechnology insider Douglas M. Hunt, Senior Vice President of Regulatory Affairs, reported two open-market sales of common stock under a pre-established Rule 10b5-1(c) trading plan. On 01/06/2026, he sold 3,973 shares at a price of $5.844 each, leaving him with 160,921 shares directly owned. On 01/07/2026, he sold another 5,014 shares at $5.879 each, after which he directly owned 155,907 shares of Puma Biotechnology common stock.
The Rule 10b5-1 plan underlying these transactions was adopted on 12-14-2020, indicating the sales were made pursuant to a pre-arranged trading instruction rather than ad hoc market timing.
Puma Biotechnology Chief Financial Officer Maximo F. Nougues reported two open-market sales of company common stock under a pre-arranged Rule 10b5-1(c) trading plan. On January 6, 2026, he sold 4,540 shares at a price of $5.844 per share, leaving him with 199,689 shares beneficially owned after that transaction. On January 7, 2026, he sold an additional 6,405 shares at $5.879 per share, resulting in 193,284 shares beneficially owned following the second sale. The filing notes that the referenced Rule 10b5-1 plan was adopted on December 14, 2020, indicating these sales were executed pursuant to that pre-established plan.
Puma Biotechnology (PBYI) reported an insider transaction by a director. On 11/11/2025, the reporting person sold 20,000 shares of common stock at a weighted average price of $4.8614, with trades executed between $4.82 and $4.97. Following the sale, the insider directly owns 54,000 shares. The filing notes the seller will provide full trade‑level details upon request.